Efficacy and safety of an innovative short-course regimen containing clofazimine for treatment of drug-susceptible tuberculosis: a clinical trial

In preclinical studies, a new antituberculosis drug regimen markedly reduced the time required to achieve relapse-free cure. This study aimed to preliminarily evaluate the efficacy and safety of this four-month regimen, consisting of clofazimine, prothionamide, pyrazinamide and ethambutol, with a st...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Xubin, Gui, Xuwei, Yao, Lan, Ma, Jun, He, Yifan, Lou, Hai, Gu, Jin, Ying, Ruoyan, Chen, Liping, Sun, Qin, Liu, Yidian, Ho, Chih-Ming, Lee, Bai-Yu, Clemens, Daniel L., Horwitz, Marcus A., Ding, Xianting, Hao, Xiaohui, Yang, Hua, Sha, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Tuberculosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026740/
https://www.ncbi.nlm.nih.gov/pubmed/36872899
http://dx.doi.org/10.1080/22221751.2023.2187247

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026740/
https://www.ncbi.nlm.nih.gov/pubmed/36872899
http://dx.doi.org/10.1080/22221751.2023.2187247

Ejemplares similares